CN

Centene CorpMOEX CNC-RM Stock Report

Last reporting period 30 Sep, 2024

Updated —

Last price

Market cap $B

39.137

Large

Exchange

MISX - Moscow Exchange

CNC-RM.ME Stock Analysis

CN

Avoid

Based on Eyestock quantitative analysis, CNC-RM.ME`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

18/100

Low score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

107.0 %

Greatly undervalued

Market cap $B

39.137

Dividend yield

Shares outstanding

551.26 B

Centene Corp. operates as a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. The company is headquartered in St. Louis, Missouri and currently employs 74,300 full-time employees. The company went IPO on 2001-12-13. The firm provides services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. The company provides a range of managed healthcare products and services, primarily through Medicaid, Medicare, and commercial products. Its segments include Medicaid, Medicare, Commercial and Other. The company offers Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace and the TRICARE program. The company also contracts with other healthcare and commercial organizations to provide a variety of specialty services focused on treating the whole person. Medicaid program provides health insurance to low-income families and individuals with disabilities. Medicare is a federal health insurance program for people ages 65 and over, which also covers people under 65 with certain disabilities and people with end-stage renal diseases.

View Section: Eyestock Rating